|
May 3
|
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
|
|
Apr 2
|
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
|
|
Mar 27
|
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
|
|
Mar 7
|
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
|
|
Sep 8
|
Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023
|
|
Sep 6
|
Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
|
|
Apr 24
|
Aditxt Announces Closing of $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
|